November Research Group has been acquired by Genpact to drive the development of their Pharmacovigilance Artificial Intelligence (PVAI) product.Genpact is a global professional services firm focused on delivering digital transformation for clients - leveraging leading digital technologies to transform industries. Genpact's Pharmacovigilance Artificial Intelligence (PVAI) will be the life sciences industry's first fully-integrated, end-to-end adverse event (AE) processing solution, leveraging intelligent automation to not only dramatically reduce the effort of processing adverse events, but also to enable an AI-driven level of real-time predictive analytics and actionable insight not previously possible. Genpact's PVAI offering brings together and integrates optical character recognition, robotic process automation, natural language processing, and machine learning technologies to automatically extract and code AE data from unstructured and semi-structured source documents - eliminating manual workflow, saving pharmaceutical companies significant time and resources, and helping to establish a scalable PV operating model. Most importantly, the solution continuously builds predictive insights as more and more AE goes through it over time. With the recent acquisition of November Research Group, Genpact can leverage NRG's domain expertise and fully-featured pharmacovigilance Software-as-a-Service to accelerate the availability of a robust product vigilance solution leveraging this transformational technology. We will be building out the PVAI solution leveraging all of the learning and technology from our PRIMO, PRIMO Mobile, PRIMO Regulatory, and Eureka products. This technology, and more importantly, our deep domain expertise, will greatly accelerate the delivery of this transformational PV solution.